


PHARMACEUTICAL 2020

BELLICUM PHARMACEUTICALS INC ** Bellicum Rank 265 of 362





PHARMACEUTICAL 2020

BELLICUM PHARMACEUTICALS INC ** Bellicum Rank 265 of 362



The relative strengths and weaknesses of BELLICUM PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BELLICUM PHARMACEUTICALS INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of BELLICUM PHARMACEUTICALS INC is the variable Net Income, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -389%, being 86% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	111,854
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	94,418
Liabilities, Non-Current	25,717
Other Assets	1,867
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	864
Other Net Income	-25,113
Property and Equipment	2,529
Research and Development	64,535
Revenues	7,143
Selling, General and Administrative Expense	29,972

Output Variable	Value in 1000 USD
Assets	116,250
Liabilities	120,999
Expenses	94,507
Stockholders Equity	-4,749
Net Income	-112,477
Comprehensive Net Income	-112,477
Economic Capital Ratio	-389%